Top Markets
Coin of the day
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Rangering i aksjer #42765
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$150.00
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Poniard Pharmaceuticals, Inc. (PARD)

Kategori

Driftsmargin for Poniard Pharmaceuticals, Inc. (PARD)
Driftsmargin per 2026 TTM: 0.00%
Ifølge Poniard Pharmaceuticals, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 0.00%. Ved slutten av 2026 hadde selskapet en driftsmargin på 0.00%.
Historikk for driftsmargin for Poniard Pharmaceuticals, Inc. fra 2026 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
Ikke nok data for de angitte datoene.
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
38.97% -
US
28.81% -
NL
0.00% -
CH
31.23% -
BE
0.00% -
KR
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.